{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:09:19Z","timestamp":1777766959721,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T00:00:00Z","timestamp":1252454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T00:00:00Z","timestamp":1252454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"abstract":"<jats:p>The effect of five antimycobacterial drugs isoniazid, rifampicin, streptomycin, pyrazinamide and ethambutol on the generation of reactive oxidants by polymorphonuclear leucocytes was investigated in vitro, using N-formyl-L-methionyl-L-leucyl-phenylalanine (FMLP) activated and spontaneous luminol-enhanced chemiluminescence and myeloperoxidase-mediated iodination. Streptomycin, pyrazinamide and ethambutol had no effect on the assays at the concentrations investigated. Isoniazid at concentrations of 1.25 and 5 \u03bcg\/ml and rifampicin at 100 \u03bcg\/ml significantly inhibited iodination. Rifampicin also caused dose-dependent inhibition of chemiluminescence, which was partly due to its light-absorbing activities. It is concluded that isoniazid, and to a lesser extent, rifampicin at therapeutic concentrations possess anti-oxidative properties.<\/jats:p>","DOI":"10.1159\/000238548","type":"journal-article","created":{"date-parts":[[2009,9,9]],"date-time":"2009-09-09T09:21:59Z","timestamp":1252488119000},"page":"56-60","source":"Crossref","is-referenced-by-count":10,"title":["Antimycobacterial Drugs and the Production of Reactive Oxidants by Polymorphonuclear Leucocytes in vitro"],"prefix":"10.1159","author":[{"given":"B.M.","family":"Zeis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,9,9]]},"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/238548","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000238548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:37:49Z","timestamp":1777477069000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000238548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,9]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000238548","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,9]]}}}